European Journal of Internal Medicine
Volume 19, Issue 5 , Pages 314-318 , July 2008

Parvovirus B19 infection and systemic lupus erythematosus: Activation of an aberrant pathway?

Received 24 April 2007 ,Accepted 26 September 2007.

References 

  1. Kurien BT, Scofield RH. Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scand J Immunol. 2006;64:227–235
  2. Zandman-Goddard G, Schoenfeld Y. Infections and SLE. Autoimmunity. 2005;38:473–485
  3. Severin MC, Levy Y, Schoenfeld Y. Systemic lupus erythematosus and parvovirus B19: causal coincidence or causative culprit?. Clin Rev Allergy Immunol. 2003;25:41–48
  4. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–1277
  5. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet. 1975;1:72–73
  6. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev. 2002;15:485–505
  7. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA. 2005;102:12891–12896
  8. Berns KI. Parvoviridae: the viruses and their replication. In:  Fields BN,  Knipe DM,  Howley PM,  Chanock RM,  Melnick JL,  Monath TP,  Roizman B,  Straus SE editor. Fields virology. Philadelphia, Pa: Lippincott-Raven; 1996;p. 2173–2197
  9. Cotmore SF, McKie VC, Anderson LJ, Astell CR, Tattersall P. Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by prokaryotic expression of isolated genomic fragments. J Virol. 1986;60:548–557
  10. Ozawa K, Ayub J, Hao YS, Kurtzman G, Shimada T, Young N. Novel transcription map for the B19 (human) pathogenic parvovirus. J Virol. 1987;61:2395–2406
  11. Tsay GJ, Zouali M. Unscrambling the role of human parvovirus B19 signaling in systemic autoimmunity. Biochem Pharmacol. 2006;72:1453–1459
  12. Christensen J, Cotmore SF, Tattersall P. Minute virus of mice transcriptional activator protein NS1 binds directly to the transactivation region of the viral p38 promoter in a strictly ATP-dependent manner. J Virol. 1995;69:5422–5430
  13. Christensen J, Pedersen M, Aasted B, Alexandersen S. Purification and characterization of the major nonstructural protein (NS-1) of Aleutian mink disease parvovirus. J Virol. 1995;69:1802–1809
  14. Christensen J, Cotmare SF, Tattersall P. A novel cellular site-specific DNA-binding protein cooperates with the viral NS1 polypeptide to initiate parvovirus DNA replication. J Virol. 1997;71:1405–1416
  15. Solheim BG, Rollag H, Svennevig JL, Arafa O, Fosse E, Bergerud U. Viral safety of solvent/detergent-treated plasma. Transfusion. 2000;40:84–90
  16. Schwarz TF, Serke S, von Brunn A, Hottentrager B, Huhn D, Deinhardt F, et al. Heat stability of parvovirus B19: kinetics of inactivation. Zentralbl Bakteriol. 1992;277:219–223
  17. Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med. 2006;260:285–304
  18. Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science. 1993;262:114–117
  19. Brown KE, Hibbs JR, Gallinella G, Anderson SM, Lehman ED, McCarthy P, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med. 1994;330:1192–1196
  20. Rouger P, Gane P, Salmon C. Tissue distribution of H, Lewis and P antigens as shown by a panel of 18 monoclonal antibodies. Rev Fr Transfus Immuno Hematol. 1987;30:699–708
  21. Srivastava A, Bruno E, Bridell R, Cooper R, Srivastava C, van Besien K, et al. Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro. Blood. 1990;76:1997–2004
  22. Weigel-Kelley KA, Yoder MC, Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol. 2001;75:4110–4116
  23. Weigel-Kelley KA, Yoder MC, Srivastava A. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood. 2003;102:3927–3933
  24. Munakata Y, Saito-Ito T, Kumura-Ishii K, Huang J, Kodera T, Ishii T, et al. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood. 2005;106:3449–3456
  25. Parvovirus B19 (erythema infectiosum, fifth disease). In: Red Book 2006: Report of the Committee on Infectious Diseases. 27th ed. Washington DC: American Academy of Pediatrics; 2006;p. 484–487
  26. Meyer O. Parvovirus B19 and autoimmune diseases. Jt Bone Spine. 2003;70:6–11
  27. White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Bacon PA. Human parvovirus arthropathy. Lancet. 1985;1:419–421
  28. Reid DM, Reid TM, Brown T, Rennie JA, Eastmond CJ. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet. 1985;1:422–425
  29. Servey JT, Reamy BV, Hodge J. Clinical presentations of parvovirus B19 infection. Am Fam Phys. 2007;75:373–376
  30. Woolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, Klouda PT, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med. 1989;149:1153–1156
  31. Takahashi Y, Murai C, Shibata S, Munakata Y, Ishii T, Ishii K, et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA. 1998;95:8227–8232
  32. Kerr JR, Boyd N. Autoantibodies following parvovirus B19 infection. J Infec. 1996;32:41–47
  33. Loizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum. 1997;40:103–108
  34. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum. 2002;31:256–263
  35. Seve P, Ferry T, Koenig M, Cathebras P, Rousset H, Broussolle C. Lupus-like presentation of parvovirus B19 infection. Semin Arthritis Rheum. 2005;34:642–648
  36. Ideguchi H, Ohno S, Ishigatsubo Y. A case of pure red cell aplasia and systemic lupus erythematosus caused by human parvovirus B19 infection. Rheumatol Int. 2007;27:411–414
  37. Caliskan R, Masatlioglu S, Aslan M, Altun S, Saribas S, Ergin S, et al. The relationship between arthritis and human parvovirus B19 infection. Rheumatol Int. 2005;26:7–11
  38. Pugliese A, Beltramo T, Torre D, Roccatello D. Parvovirus B19 and immune disorders. Cell Biochem Funct 2006 [epub Aug. 18].
  39. Nesher G, Osborn T, Moore TL. Parvovirus infection mimicking systemic lupus erythematosus. Semin Arthritis Rheum. 1995;24:297–303
  40. In:  Zouali M editors. Molecular autoimmunity. New York: Springer Science/Business Media, Inc.; 2005;p. 437
  41. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. 2006;19:80–94
  42. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med. 1999;341:2068–2074
  43. Lunardi C, Tiso M, Borgato L, Nanni L, Millo R, De Sandre G, et al. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol. 1998;28:936–948
  44. Gasser S, Raulet D. The DNA damage response, immunity and cancer. Semin Cancer Biol. 2006;16:344–347
  45. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1994;152:3685–3692
  46. Quinn JP, Simpson J, Farina AR. The Ku complex is modulated in response to viral infection and other cellular changes. Biochim Biophys Acta. 1992;1131:181–187
  47. Mimori T, Hardin JA. Mechanism of interaction between Ku protein and DNA. J Biol Chem. 1986;261:10375–10379
  48. Reeves WH. Antibodies to the p70/p80 (Ku) antigens in systemic lupus erythematosus. Rheum Dis Clin North Am. 1992;18:391–414
  49. Reeves WH, Satoh M, Wang J, Chou CH, Ajmani AK. Systemic lupus erythematosus. Antibodies to DNA, DNA-binding proteins, and histones. Rheum Dis Clin North Am. 1994;20:1–28

PII: S0953-6205(07)00286-5

doi: 10.1016/j.ejim.2007.09.013

European Journal of Internal Medicine
Volume 19, Issue 5 , Pages 314-318 , July 2008

Article Tools